Extranodal natural killer T-cell lymphoma, nasal-type—A new staging system from CSWOG—A multicenter study.

Lin, Tongyu; Hong, Huangming; Liang, Chaoyong; Huang, He; Guo, Chengcheng; Tian, Ying; Liu, Tingzhi; Zhang, Mengping; Li, Xueying; Fu, Xiaohong; Wang, Zhao; Fang, Xiaojie; Lin, Xun; Li, Shanshan; Lin, Jia Tian; Prem, Raj Shrestha; Ye, Sheng; Yi, Jiqun; Deng, Yanhong; Xiao, Jian

doi:10.1200/jco.2014.32.15_suppl.8552

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone marrow aspiration and biopsy were applied to assess bone marrow invasion. The clinical stage standard proposed by Lin et al 13 was adopted. International Prognostic Index scores were used to evaluate the risk for patients with ENKL.…”

Section: Meaningmentioning

confidence: 99%

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEThe L-asparaginase-based SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide) chemotherapy regimen has shown higher response rates and survival benefit over an anthracycline-containing regimen. However, the safety profile was not satisfied. A well-tolerated regimen with promising efficacy is lacking.OBJECTIVE To compare the efficacy and safety of the DDGP (dexamethasone, cisplatin, gemcitabine, and pegaspargase) regimen with the SMILE regimen in newly diagnosed advanced-stage (III/IV) extranodal natural killer/T-cell lymphoma (ENKL). DESIGN, SETTING, AND PARTICIPANTSThis was an open-label, multicenter, randomized clinical trial that took place across 12 participating hospitals in China from January 2011 to February 2019. Patients were eligible if they were 14 to 70 years old with newly diagnosed ENKL in stages III/IV and had an Eastern Cooperative Oncology Group performance status of 0 to 2. Eligible patients were evenly randomized to either the DDGP or SMILE group.INTERVENTIONS Patients in each group were treated with the assigned regimen every 21 days for 6 cycles. MAIN OUTCOMES AND MEASURESThe primary end point was progression-free survival (PFS), and secondary end points included overall response rate and overall survival (OS). The adverse events between the DDGP and SMILE groups were compared. RESULTS Among the 87 randomized patients, 80 received treatment (40 in the DDGP group and 40 in the SMILE group); the median (IQR) age was 43 (12) years, and 51 (64%) were male. The baseline characteristics were similar between the groups. At a median follow-up of 41.5 months, the median PFS was not reached in the DDGP group vs 6.8 months in the SMILE group (HR, 0.42; 95% CI, 0.23-0.77; P = .004), and the median OS was not reached in the DDGP group vs 75.2 months in the SMILE group (HR, 0.41; 95% CI, 0.19-0.89, P = .02). The PFS rate at 3 years and OS rate at 5 years were higher in the DDGP group vs the SMILE group (3-year PFS, 56.6% vs 41.8%; 5-year OS, 74.3% vs 51.7%). The overall response rate was higher in the DDGP group than in the SMILE group (90.0% vs 60.0%; P = .002). Grade 3 and 4 hematologic toxic effects were more frequently reported in the SMILE group vs the DDGP group (leukopenia, 85.0% vs 62.5%; neutropenia, 85.0% vs 65.0%). CONCLUSIONS AND RELEVANCEIn this randomized clinical trial, the DDGP regimen showed promising preliminary results for patients with newly diagnosed local advanced ENKL. A confirmation trial based on larger population is warranted.

show abstract

Section: Meaningmentioning

confidence: 99%

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Inclusion Criteria were as follows: (1) Age range 14-70 years old; (2) ECOG performance status 0-2; (3) Estimated survival time > 3 months; (4) Histological confirmed NK/T cell lymphoma, nasal-type according to WHO classification [ 26 ]; (5) The NSS [ 27 ] stage III or IV; (6) None of chemotherapy or radiotherapy has been previously used; (7) None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×10 9 /L, platelet ≥ 100×10 9 /L, ALT and AST ≤ 2×upper limitation of normal (ULN), serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×ULN, Serum Albumin ≥ 30g/L, serum plasminogen is normal; (8) At least one measurable lesion; (9) None of other serious diseases, cardiopulmonary function is normal; (10) Pregnancy test of women at reproductive age must be negative; (11) Patients could be followed up; (12) None of other relative treatments including the traditional Chinese medicine, immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic treatments; (13) Volunteers who signed informed consent.…”

Section: Methodsmentioning

confidence: 99%

“…Clinical stage based on the NSS which was established by Tongyu Lin [ 27 ]. Stage III was defined localized disease with regional lymph node involvement (cervical lymph nodes); and stage IV: disseminated disease (lymph nodes on both sides of diaphragm, multiple extranodal site).…”

Section: Methodsmentioning

confidence: 99%

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149

Zhang

Sisi

et al. 2016

Oncotarget

View full text Add to dashboard Cite

To explore a more effective treatment for newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), we conducted a phase 4 study of the cisplatin, dexamethasone, gemcitabine, pegaspargase (DDGP) regimen. The primary end point was the 2-year progression-free survival (PFS) after the protocol treatment. Secondary endpoints included response rate (RR), overall survival (OS) and median survival time (MST). The interim analysis included data only from March 2011 to September 2013, who received six cycles of DDGP chemotherapy. A total of 25 eligible patients were enrolled. Seventeen patients (17/24, 70.83%) achieved complete response (CR) and four (4/24, 16.67%) achieved partial response (PR), three (3/24, 12.50%) had progressive disease (PD). The RR after treatment was 87.50%. After a median follow-up duration of 24.67 months (range 4-48 months). The 2-year PFS and OS rate were 61.80% (95% CI, 42.00% to 81.60%) and 68.50 % (95% CI, 48.70% to 88.30%), respectively. The MST was 36.55 months (95% CI, 29.41 months to 43.70 months). Grade 3/4 leukopenia occurred in fourteen patients (58.33%) and grade 3/4 thrombocytopenia occurred in eleven patients (45.83%). Twelve patients (50.00%) experienced Activated Partial Phromboplastin Ptime (APTT) elongation and fourteen patients (58.33%) experienced hypofibrinogenemia. In conclusion, DDGP regimen is an effective and tolerated treatment for newly diagnosed, advanced-stage ENKTL. This trial was registered at www.ClinicalTrials.gov as #NCT01501149.

show abstract

Extranodal NK-T Cell Lymphoma, Nasal Type: Retrospective Analysis of Real-World Data

Bothra

Bhandari

Agrawal

et al. 2019

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Extranodal natural killer T-cell lymphoma, nasal-type—A new staging system from CSWOG—A multicenter study.

Cited by 4 publications

References 0 publications

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149

Extranodal NK-T Cell Lymphoma, Nasal Type: Retrospective Analysis of Real-World Data

Contact Info

Product

Resources

About